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Abstract 
Alcoholic hepatitis (AH) develops only in small proportion of heavy drinkers. To better 
understand the mechanisms underlying this disparity, we conducted a study to define the 
relationship between AH development and dysregulated immune responses that might be 
ameliorated by alcohol abstinence. Sixty-eight AH patients, 65 heavy drinking controls without 
liver disease (HDC), and 20 healthy controls (HC) were enrolled and followed up to 12 months. 
At the baseline, HDC and HC had no significant differences in their plasma levels of 38 
inflammatory cytokines/chemokines measured using multiplex immunoassays. However, 
compared to HDC, AH patients had higher baseline levels of 11 cytokines/chemokines (TNF-α, 
IL-6, IL-8, IP10, IL-4, IL-9, IL-10, FGF-2, IL-7, IL-15, and TGF-α), but lower levels of the anti-
inflammatory macrophage-derived chemokine (MDC). AH patients also had more activated, yet 
dysfunctional immune cells as monocytes, T cells, and B cells expressed higher levels of CD38 
and CD69, but low levels of HLA-DR, CD80, and CD86 at baseline. In addition, CD4 T cells 
produced less IFN-γ in response to T cell stimulation. Upregulated IL-6, IL-8, CD38, and CD69 
and downregulated MDC, HLA-DR, CD86, and CD80 correlated positively and negatively, 
respectively, with disease severity. Longitudinal analysis indicated that levels of IL-6, IL-8, 
CD38, and CD69 were reduced, whereas levels of MDC, HLA-DR, CD80, and CD86 were 
increased in abstinent AH patients. All of the cellular immune abnormalities were reversed by 
day 360 in abstinent AH patients; however, plasma levels of TNF-α, IL-8, IL-10, FGF-2, and IL-7 
remained higher. Conclusion: AH patients were in a highly immune-dysregulated state, 
whereas HDC showed little evidence of immune activation. Alcohol abstinence reversed most, 
but not all, of the immunological abnormalities.  
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Introduction 
More than 2 billion people worldwide consume alcohol on a regular basis.  Of these, 
approximately 76 million suffer from alcohol-related disorders (1). Long-term heavy drinkers 
develop a spectrum of severe alcoholic liver disease (ALD), ranging from alcoholic hepatitis 
(AH), fibrosis/cirrhosis, to hepatocellular carcinoma (HCC) (2). AH is a severe and progressive 
liver inflammatory disease associated with significant morbidity and mortality, for which there 
are no effective medical therapies (3-5). Alcohol-induced dysregulation of both innate and 
adaptive immune systems has been implicated in the pathogenesis of AH (6-8). 
Heavy alcohol consumption causes over-activation of innate immunity components in both 
the peripheral blood and the liver tissue by way of gut-derived bacterial toxins such as 
lipopolysaccharides (LPS) and the hepatic stress of alcohol metabolism (9, 10). Consequently, 
AH patients have elevated circulating levels of a variety of pro-inflammatory factors in 
association with elevated anti-inflammatory and hepatoprotective cytokines, such as IL-10 (11, 
12). Studies have demonstrated that circulating levels of TNF-α, IL-6, IL-8, MCP-1, and 
MIP3α correlate with the severity of AH and that two of them (TNF-α and IL-6) also correlate 
with AH mortality (13-16). Abstinence from alcohol improves clinical symptoms for most AH 
patients and has been shown to reduce IL-6 level (17, 18). Increased hepatic oxidative stress 
and over-activation of liver cells, including resident macrophages (Kupffer cells) and 
hepatocytes, have also been observed in AH patients (9, 10). These alternations increase 
infiltration of inflammatory cells including monocytes, neutrophils, and T cells into the liver, 
leading to liver damage (16, 19). 
Alcohol abuse also impairs the adaptive immune system (6, 20). Studies in both humans 
and animal models have demonstrated that chronic alcohol abuse has a significant impact on T 
cell biology including a reduction in count, impairment of development and function, disturbance 
of the balance between effector and regulatory T cell types, influence of phenotype and 
activation, and promotion of cell apoptosis (6, 20). Alcohol abuse also affects multiple aspects of 
B cell-mediated immunity (6, 21, 22), leading to reduced numbers and function of B cells while 
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simultaneously increasing production of immunoglobulins (6, 21, 22). Particularly, the levels of 
autoantibodies against liver-specific antigens are increased in AH patients and may promote 
alcohol-related liver damage (6). Due to alcohol-induced impairment of both innate and adaptive 
immunity, chronic alcohol drinkers are more susceptible to many infectious pathogens with 
delayed infection recovery, thus extending hospital stays and increasing morbidity and mortality 
(23).  
The reason why alcohol abuse causes AH in a subset of patients with excessive alcohol 
use and what determines the severity of AH has not yet been fully understood. Most previous 
studies have compared AH patients with healthy controls (HC) or patients with clinically stable 
alcoholic cirrhosis to try to understand the immunological differences underlying the apparent 
individual susceptibility to AH.  We conducted a study to define the relationship between AH and 
dysregulated immune responses among heavy drinkers with or without AH and to investigate 
immune recovery associated with alcohol abstinence. 
 
Materials and Methods 
 
Study Subjects and Blood Samples 
The sixty-eight AH patients and 65 HDC included in this study were enrolled into the 
ongoing multicenter prospective Translational Research and Evolving Alcoholic Hepatitis 
Treatment 001 study (TREAT 001, NCT02172898). Demographic and clinical characterizations 
as well as drinking patterns of the study subjects are shown in Table 1. Detailed definitions of 
AH and HDC and the inclusion and exclusion criteria were previously described (24). Briefly, AH 
was defined as the onset of AST >50 IU/L and elevated total bilirubin (initially >2 mg/dL but 
amended to >3 mg/dL) (25) in patients with a long drinking history who were drinking heavily 
within the 6 weeks prior to enrollment. A liver biopsy was performed to confirm AH diagnosis in 
patients with uncertainty about drinking history or atypical clinical features. HDC were 
individuals with a comparable history of alcohol consumption but had no clinical evidence of 
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liver disease (AST ≤ 50 U/L, ALT≤ 50 U/L, total bilirubin within normal limits) and were matched 
for age and sex. The study was approved by the Institutional Review Boards at Indiana 
University School of Medicine and Mayo Clinic. All participants provided a written informed 
consent. 
Peripheral blood was collected in heparin-coated tubes (BD Biosciences, Franklin Lakes, 
NJ). Plasma and peripheral blood mononuclear cells (PBMCs) were isolated and stored at -
80oC until use. Baseline AH samples were taken at presentation. For AH patients treated with 
corticosteroids and/or pentoxifylline, samples were taken within a few days of treatment. Some 
study subjects were fasting before the blood draw (Table 1). Plasma samples from 20 age- and 
sex-matched healthy volunteers without self-reported excessive drinking history were also 
included as HC. 
 
Multiplex Immunoassays and Enzyme-linked Immunosorbent Assay (ELISA) 
Plasma concentrations of 38 cytokines/chemokines (sCD40L, EGF, Eotaxin, FGF-2, Flt-3 
ligand, fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, 
IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, IP-10, MCP-1, 
MCP-3, MDC, MIP-1α, MIP-1β, TGF-α, TNF-α, TNF-β, and VEGF) were simultaneously 
measured using a magnetic bead-based multiplex kit (HCYTMAG-60K-PX38, EMD Millipore, 
Billerica, MA). The concentrations of cytokines/chemokines were calculated using the Bio-Plex 
Manager v6.1 software (Bio-Rad, Hercules, CA). For statistical analyses, values below the 
detection limit of the assay were replaced with the minimal detectable concentrations for each 
analyte as provided by the manufacturer. 
Plasma concentrations of IL-6, IL-8, and MDC were also measured using IL-6 and IL-8 
High Sensitivity quantikine ELISA kits, and the Human CCL22/MDC DuoSet ELISA kit (R&D 
Systems, Minneapolis, MN), respectively, to validate the multiplex immunoassay results.  
 
Flow Cytometry 
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PBMCs were subjected to cell surface staining and intracellular staining (ICS) to determine 
leukocyte phenotype, activation, and immune response. For cell surface staining, PBMCs were 
incubated with fluorochrome-conjugated antibodies against CD4, CD8, CD14, CD16, CD19, 
CD38, CD69, CD80, CD86, and HLA-DR (Biolegend, San Diego, CA). Stained cells were fixed 
with 2% paraformaldehyde (PFA) and subsequently analyzed using a SORP FACSAria 
cytometer (BD Biosciences, San Jose, CA). For ICS, PBMCs were cultured for 24 h in complete 
RPMI 1640 medium containing 1 µg/ml of soluble anti-CD28 antibody (clone 28.1) and 20 U/ml 
human IL-2 in flat-bottomed 96-well plates pre-coated with 1 µg/ml of anti-CD3 antibody (clone 
OKT3). Brefeldin A (eBioscience, San Diego, CA) was added to a final concentration of 3 µM for 
the last 6 h of incubation. Stimulated cells were stained with CD3, CD4, CD8, and IFN-γ 
antibodies using the Cytofix/Cytoperm kit (BD Biosciences, San Jose, CA). Flow data were 
analyzed using FlowJo v10 software (Tree Star, San Carlos, CA).  
 
Statistical Analysis 
Differences in cross-sectional analysis for continuous variables between 2 groups were 
calculated using Mann Whitney test and Kruskal-Wallis test with Dunn’s corrections for 
comparisons among 3 groups. Chi-square test was used for comparison between groups for 
categorical variables. The linear relationship between two variables was analyzed using the 
Spearman correlation test. Differences in longitudinal analysis were calculated using Friedman 
rank sum test with Dunn’s corrections. P <0.05 was considered to be statistically significant. 
 
Results 
Characteristics of the Study Cohort 
Table 1 shows characteristics of AH patients, HDC, and HC. Fasting rates at baseline and 
6-month and one-year follow-up were similar between AH patients and HDC, but a higher 
percentage of HC were fasting as compared to HDC. Age and gender distributions and 
creatinine levels were comparable among the three groups. The HDC had significantly more 
Page 7 of 36
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
   
8 
 
drinks in the last 30 days before the enrollment than AH patients. As expected, the baseline 
MELD score and liver biochemistries (AST, ALT, and total bilirubin) were highly elevated in AH 
patients in comparison with HDC and HC. Prothrombin time was significantly increased in the 
AH patients than HDC. In addition, the median neutrophil counts were also significantly higher 
(p< 0.001) in AH patients (6.35x109/L; interquartile range [IQR]: 4.1-15.0, n=48) than in HDC 
(3.3x109/L; IQR: 2.5-4.5, n=56). Although HDC and HC had similar amounts of total bilirubin and 
AST, HDC had higher levels of ALT than HC. Thirty-nine AH patients were treated with 
corticosteroids and/or pentoxifylline (25 with steroids, 3 with pentoxifylline, and 11 with both) at 
the discretion of treating physicians. Fifteen AH patients (26%) died within 6 months after 
recruitment. The complete abstinence rate was 64% and 72% for AH patients and 42% and 
50% for HDC at days 180 and 360, respectively. The liver biochemistries markedly improved in 
AH patients and remained unchanged for HDC. However, the MELD scores, total bilirubin and 
AST, and prothrombin time remained abnormal in abstinent AH patients at 12 months 
(Supporting Table 1).   
 
AH Patients Had Dysregulated Plasma Levels of Pro-inflammatory and Anti-inflammatory 
Cytokines/Chemokines 
To assess immune characteristics in the peripheral blood from AH patients and HDC, we 
first performed multiplex immunoassays to quantify plasma levels of 38 human inflammatory 
cytokines/chemokines. Plasma samples from 20 healthy volunteers were used as HC. The 
cross-sectional analysis results are summarized in Table 2 and Supporting Table 2. Compared 
to the HDC group, AH patients had significantly higher baseline plasma levels of 11 
cytokines/chemokines including 4 pro-inflammatory cytokines/chemokines (TNF-α, IL-6, IL-8, 
and IP10), 3 anti-inflammatory cytokines (IL-4, IL-9, and IL-10), and 4 growth factors (FGF-2, IL-
7, IL-15, and TGF-α). IL-6 is a multifunctional cytokine that can have both pro-inflammatory and 
hepatoprotective effects in AH (12, 26) and was classified as a pro-inflammatory cytokine in this 
study. At day 180, the 4 upregulated pro-inflammatory cytokines/chemokines (TNF-α, IL-6, IL-8, 
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and IP10) remained significantly higher in AH patients than in HDC. At day 360, 3 pro-
inflammatory cytokines (TNF-α, IL-6, and IL-8) were still higher while 2 anti-inflammatory 
cytokines (IL-9 and IL-10) and 2 growth factors (FGF-2 and IL-7) were resumed among the 11 
upregulated factors in AH patients. However, by day 180 and day 360, IL-6 and IL-8 levels 
greatly decreased from the baseline values in AH patients while remaining unchanged in HDC. 
Interestingly, MDC, an anti-inflammatory macrophage-derived chemokine, was the only 
cytokine/chemokine whose baseline level was significantly lower in AH patients than in HDC, 
but at day 360 MDC levels became higher in AH than in HDC. These results indicate that pro-
inflammatory cytokines/chemokines decreased while anti-inflammatory factors increased in AH 
patients over the time of one-year observation.  
We next compared baseline plasma levels of 38 cytokines/chemokines in AH patients and 
HDC with HC (Table 2 and Supporting Table 2). AH patients had significantly higher levels of 
TNF-α, IL-6, IL-7, IL-8, IP-10, IL-10, IL-15, and TGFα at recruitment than HC. We also detected 
an additional cytokine (IFNα2) that was upregulated in AH patients. In contrast, the plasma 
levels of the 38 cytokines/chemokines analyzed were not significantly different between HDC 
and HC. 
We used IL-6 and IL-8 ELISAs to validate the multiplex results, as IL-6 and IL-8 were the 
most highly upregulated cytokines in AH patients (Supporting Table 2). ELISA data showed that 
IL-6 and IL-8 levels were significantly higher in AH patients than in HDC (Fig. 1A, 1B). In 
addition, cytokine levels measured by the two methods were significantly correlated (Fig. 1C). 
As MDC was a novel marker not previously identified in AH patients, we also quantified MDC 
levels by ELISA. We confirmed that MDC plasma levels were significantly lower and higher in 
AH patients than HDC at baseline and day 360, respectively. Furthermore, MDC levels 
determined by the two techniques were significantly correlated (Fig. 1C).  
Together, our data indicated that AH patients had a highly dysregulated and persistent 
production of inflammatory cytokines/chemokines as compared to HDC and HC, whereas HDC 
did not show evidence of inflammatory factors in comparison with HC.  
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Cellular Markers of Immune Activation Were Highly Dysregulated in AH Patients 
As cytokines/chemokines regulate activation and function of both the innate and adaptive 
immune cells, we analyzed activation status of immune cells in PBMC samples from these 
subjects. Compared with HDC, monocytes from AH patients expressed higher levels of the 
activation markers CD38 and CD69 (% and median fluorescent intensity, MFI), but lower levels 
of the antigen-presenting molecules MHC II HLA-DR (MFI) and the costimulatory molecules 
CD80 (% and MFI) and CD86 (MFI) at baseline (Table 3 and Supporting Table 3). These results 
suggest that monocytes in AH patients are aberrantly activated and would have impaired 
capacity to activate antigen-specific T cells due to low expression of HLA-DR and costimulatory 
molecules. Further analyses demonstrated that AH patients still had significantly lower levels of 
CD80 (% and MFI) and CD86 (MFI) at day 180, but by day 360 all these markers were similarly 
expressed on monocytes in both AH and HDC groups. The recovery expression of 
costimulatory molecules on monocytes in AH patients by day 360 is likely due to alcohol 
abstinence as majority of AH patients achieved alcohol abstinence by the time point. In fact, the 
results were similar to those obtained from the comparison between abstinent AH patients and 
HDC (data not shown).  
We next compared T cell immunity in AH patients and HDC (Table 3 and Supporting Table 
3). We found that baseline frequency of CD8 T cells was decreased in AH patients. In addition, 
AH patients had a higher % of CD69-expressing CD4 and CD8 T cells, and a higher % of CD38-
expressing CD8 T cells. At follow-up, expression of these T cell markers became comparable 
between AH and HDC groups. The frequency of CD69-expressing CD8 T cells remained higher 
in AH patients at day 360, but this difference was not seen when comparing cells from abstinent 
AH patients and HDC (data not shown). We also examined the functional capacity of T cells to 
produce IFN-γ in response to T cell receptor (TCR) stimulation, and found that the CD4 cells 
from AH patients produced significantly less IFN-γ (Table 3 and Supporting Table 3). For B cells, 
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CD80 expression (% and MFI) was reduced in AH patients at baseline, but there were no 
differences at follow-up time points.  
Taken together, the peripheral blood immune cells in AH patients expressed higher levels 
of activation markers, but low levels of antigen-presentation and co-stimulatory molecules, and 
the CD4 T cells had reduced responses to TCR stimulation. All of the cellular immune 
abnormalities were reversed by day 360 with alcohol abstinence. 
 
Correlation of Immune Markers with Clinical Profiles of AH Patients 
To explore whether the differentially-expressed immune factors play a pathogenic role in 
AH, we performed linear regression analysis to detect their correlation with disease severity 
represented by clinical scores (MELD score) and biochemical measurements (AST, ALT, total 
bilirubin, creatinine, and prothrombin time) in AH patients. Immunoprofiling data as well as 
neutrophil counts at enrolment and follow-ups were pooled for these analysis and the results are 
summarized in Supporting Table 4. Blood neutrophil counts had significantly correlations with 
multiple clinical indicators of disease severity (MELD score, total bilirubin, AST, and prothrombin 
time). IL-6 and IL-8 levels were highly correlated with clinical parameters such as MELD score. 
In addition, circulating levels of IL-8, a potent chemoattractant for neutrophils, were also strongly 
correlated with neutrophil counts (Spearman coefficient of 0.65, p<0.0001). IL-15, TGF-α, and 
TNF-α showed significant but weak correlations with clinical parameters. MDC was negatively 
correlated with disease severity, as indicated by MELD score, total bilirubin, prothrombin time, 
and AST. Similarly, upregulated cellular activation markers (CD38 on monocytes and CD8 T 
cells, CD69 on both CD4 and CD8 T cells) were positively correlated with MELD score, total 
bilirubin, and AST. In contrast, downregulated cellular markers CD80, CD86, and HLA-DR on 
monocytes and CD80 on B cells showed negative correlations with MELD score, total bilirubin, 
and AST.  
We next compared the baseline levels of immune parameters in AH patients who died 
within the 6-months and survivors to identify markers associated with 6-month mortality. The 
Page 11 of 36
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
   
12 
 
only marker that was differentially expressed was CD38 MFI on monocytes, with the non-
survivors having lower levels (Supporting Fig. S1). Further, we investigated if any of the 
immunoparameters could predict survival by performing Kaplan-Meier survival analysis. Again, 
the only parameter that predicted 90-day or 180-day mortality was the level of CD38 expression 
(MFI) on monocytes (using MFI of 2999 as cut-off value). AH patients with lower CD38 
expression had higher 90-day and 180-day mortality (Fig. 2A). 
Thirty-nine of the 68 AH patients were treated with the corticosteroid prednisone and/or 
pentoxifylline, two drugs that suppress inflammation in AH patients through different 
mechanisms. Corticosteroids reduce pro-inflammatory cytokines and increase anti-inflammatory 
cytokines, whereas pentoxifylline mainly inhibits TNF-α production. To determine how the 
steroid treatment impacted the immunoprofiles in AH patients, we compared immune markers in 
AH patients treated with prednisone alone or together with pentoxifylline and in untreated 
patients. As shown in Fig. 2B and Supporting Table 5, levels of IL-6, IL-7, IL-9, TNF-α, IFNα2, 
G-CSF, and fractalkine were lower in the treated group. However, treated patients still had 
higher levels of inflammatory cytokines IL-8 and eotaxin, and lower MDC levels (Fig. 2B and 
Supporting Table 5). Treatment also improved T cell function as CD4 and CD8 T cells in treated 
patients had enhanced capacity to produce of IFN-γ in response to TCR stimulation. 
Interestingly, treated patients still had increased frequencies of CD38-expressing monocytes 
(Supporting Table 5). The remaining immune markers did not show differences between treated 
and untreated patients (Supporting Table 5 and data not shown). 
We next examined whether treatment with corticosteroids had an impact on immune 
responses at follow-ups in alcohol abstinent AH patients. At days 180 and 360, levels of all 
immune markers except the frequency of CD38-expressing monocytes were similar between 
the treated and untreated patients (Supporting Table 5). It is pertinent to note that treated AH 
patients had higher MELD score, total bilirubin level, and longer prothrombin time, but similar 
levels of creatinine, AST, and ALT (Supporting Fig. S2), indicating that treated patients had 
more severe liver disease than untreated patients at the study entry. 
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Taken together, our data suggested that corticosteroids reduced dysregulation of most but 
not all of the immune mediators and that steroid treatment did not appear to have additional 
long-term immunological benefits in alcohol abstinent AH patients.  
 
Longitudinal Analysis of Plasma Levels of Cytokines/Chemokines and Activation of 
Immune Cells in Alcohol Abstinent AH and HDC 
Longitudinal analysis of plasma levels of cytokines/chemokines showed that alcohol 
abstinent only ameliorated dysregulated levels of IL-8 and MDC in AH patients. As shown in Fig. 
3A, plasma levels of IL-8 and MDC were significantly reduced and increased, respectively, in 
AH patients at day 180 versus baseline. Plasma levels of IL-8 still remained significantly lower 
and MDC levels remained higher (although was not significant) at day 360 versus baseline (Fig. 
3A). IL-6 levels in AH patients trended to be lower during follow-up (p=0.08) (date not shown). 
IL-6, IL-8, and MDC levels in the HDC did not show longitudinal changes (Fig. 3B). Consistent 
with these finding that the majority of the 12 dysregulated cytokines/chemokines did not show 
significant longitudinal changes in alcohol abstinent AH patients, cross-sectional analysis of 
day-180 and day-360 follow-up samples from alcohol abstinent AH patients and HDC revealed 
that AH patients still had significantly higher levels of TNF-α, IL-6, IL-8, and IP10 at day 180 and 
TNF-α, IL-6, IL-8, IL-7 and FGF-2 at day 360 (Supporting Table 6). 
We next examined longitudinal changes of the cell activation and costimulatory markers 
that were differentially expressed in AH patients and HDC. Expression levels of CD69 (%) on 
CD4 T cells were significantly reduced in AH only at day 360 (Fig. 4A); expression of CD38 on 
monocytes (MFI) in AH trended to be lower during follow-up (p=0.085). Concurrently, CD80 
levels on monocytes were increased by days 180 and 360 in AH patients, and CD86 and HLA-
DR MFI on monocytes and CD80 MFI on B cells were also increased by day 360 (Fig. 4A and 
Supporting Fig. S3) in AH patients. Interestingly, monocytes from HDC also upregulated CD80 
and CD86 expression at day 360 (Fig. 4B), suggesting that heavy drinking also led to 
phenotypical abnormalities in their monocytes at recruitment even in those without AH.  
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Together, our data indicated that the dysregulated cytokines/chemokines and cellular 
immune markers in AH patients as well as HDC improved with alcohol abstinence.  
 
Discussion 
In the present study, we performed a comprehensive cross-sectional and longitudinal 
analysis of soluble and cellular immune markers in the peripheral blood of a large cohort of AH 
patients and matched heavy drinkers without liver disease as well as healthy controls (Table 1). 
This is a major advantage of our study, as it can identify (1) changes related to heavy drinking 
alone, (2) changes that occur when AH develops, and (3) immune recovery following alcohol 
abstinence. We demonstrated that HDC had few indications of dysregulated immune profiles 
(Table 2). In contrast, AH patients exhibited a highly dysregulated production of 
cytokines/chemokines, immune cell activation, and neutrophilia when compared to HDC or HC 
(Tables 2, 3). We identified 11 upregulated cytokines/chemokines, including 4 pro-inflammatory 
cytokines (TNF-α, IL-6, IL-8, and IP10), 3 anti-inflammatory cytokines (IL-4, IL-9, and IL-10), and 
4 growth factors (FGF-2, IL-7, IL-15, and TGF-α) and 1 downregulated chemokine (MDC) 
(Table 2). Both monocytes and T cells upregulated the cell activation markers CD38 and CD69, 
whereas monocytes and B cells downregulated the antigen-presenting molecules HLA-DR and 
the costimulatory molecules CD80 and CD86 (Table 3).  Levels of upregulated IL-6, IL-8, CD38, 
CD69, and neutrophil count positively correlated with disease severity of AH, whereas 
downregulated CD80, CD86, HLA-DR, and MDC showed negative correlations (Supporting 
Table 4). CD38 expression levels on monocytes predicted 3-month and 6-month mortality. 
Analysis of follow-up and longitudinal samples indicated the immune markers in AH patients 
drastically improved but were not completely recovered with alcohol abstinence, which is 
consistent with changes in their clinical profiles. 
Of the 12 dysregulated cytokines/chemokines identified in our study, the pro-inflammatory 
cytokines/chemokines (TNF-α, IL-6, IL-8, and IP10), the anti-inflammatory cytokines (IL-4 and 
IL-10), and the growth factor IL-15 have been shown to be elevated in patients with ALD in 
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comparison to HC or those with stable alcoholic cirrhosis (13, 14, 18, 27, 28). Serum IL-7 
concentration is higher in alcohol-dependent individuals without clinical AH than HC (29). We 
found that IL-8, a potent neutrophil chemotactic factor, was the most highly upregulated cytokine 
in AH patients and remained higher in abstinent AH patients. In addition, IL-8 accumulation was 
more resistant to corticosteroid treatment than other pro-inflammatory cytokines, such as IL-6 
and TNF-α. IL-8 levels were highly correlated with disease severity and neutrophilia. Hepatic 
neutrophil infiltration and neutrophilia are prominent features of AH, which correlate with disease 
severity (25). Future study on the relationship between IL-8 and activation/function of both 
circulating and hepatic neutrophils are warranted. Furthermore, our findings lend support to the 
blockade of IL-8 as a therapeutic strategy to reduce hepatic neutrophil infiltration and AH 
severity as demonstrated recently in an experimental ALD model (30). 
We also identified 4 novel cytokines/chemokines (TGF-α, FGF-2, IL-9, and MDC) that 
were differentially expressed in AH patients. TGF-α binding to its receptor EGFR (epidermal 
growth factor receptor) stimulates hepatocyte proliferation during liver regeneration after toxic 
liver injury (31). As TGF-α levels correlated with AH severity, upregulation of TGF-α might 
represent a failed attempt to repair liver damage through liver regeneration. Level of the 
multifunctional protein fibroblast growth factor 2 (FGF-2) increased with the progression of 
chronic liver diseases from chronic hepatitis to liver cirrhosis and HCC (32), and is implicated in 
hepatic fibrogenesis (33). The elevated levels of FGF-2 may reflect the observation that nearly 
all AH patients have some degree of fibrosis at diagnosis (34). IL-9 is mainly produced by Th9 
and Th17 cells, two subsets of CD4 T cells. It is possible that enhanced levels of IL-9 in AH 
patients contribute to alcohol-induced intestinal permeability, as IL-9 impairs intestinal barrier 
functions in patients with ulcerative colitis (35). 
MDC was downregulated in AH patients as compared to HDC. MDC is produced by 
dendritic cells (DCs) and macrophages, in particular, the activated anti-inflammatory and tissue-
repairing M2 type of macrophages (36). Alcohol is known to suppress the differentiation of M2 
macrophages and skew macrophages towards the pro-inflammatory M1 type in ALD patients, 
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whereas M2 hepatic macrophages protect against ALD (37). MDC is a chemotactic ligand for 
the chemokine receptor CCR4, which is preferentially expressed on Th2 lymphocytes, skin-
homing T cells, and the immunosuppressive regulatory T cells (Tregs) (38). MDC not only 
recruits Tregs to the sites of inflammation, it also activates and enhances Treg function (39). 
Interestingly, serum levels of MDC are also lower in patients with chronic inflammatory liver 
diseases such as primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune 
hepatitis than HC (38). We speculate that predominant M1 polarization in ALD leads to reduced 
production of MDC and subsequently fewer Tregs infiltrating the liver and more severe liver 
inflammation. Therefore, MDC augmentation may be explored as a potential new immune 
modulation therapy to attenuate AH and other inflammatory liver conditions. 
The immunosuppressive cytokine IL-10 was among the highly upregulated circulatory 
factors in AH patients. IL-10 suppresses the production of pro-inflammatory cytokines by many 
cell types such as Kupffer cells, monocytes, and T cells. IL-10 also downregulates expression of 
HLA-DR, CD80, and CD86 on professional antigen-presenting cells (APCs), including 
monocytes/macrophages, DCs, and B cells, thereby impairing T cell activation. Indeed, the 
baseline expression levels of these molecules were greatly reduced on monocytes and B cells 
in AH patients. Thus, the increased level of IL10 may contribute to these changes in the 
circulating APCs. Alcohol has been shown to reduce CD80 and CD86 expression on DCs and 
DC co-stimulatory function (40). It is likely that reduced expression of HLA-DR, CD80, and 
CD86 on various APCs leads to suboptimal function of pathogen-specific T cells, which 
contributes to the discordance between heightened immune activation and increased 
susceptibility and severity to infections as observed in AH patients (20, 41, 42). 
Both monocytes and CD8 T cells in AH patients expressed significantly higher levels of 
CD38 (Tables 3 and Supporting Table 3). CD38 has diverse functions in T cell activation and 
proliferation, cytokine release, and monocyte chemotaxis towards sites of inflammation, and 
adhesion of T cells and monocytes to endothelial cells. As one of the pathophysiological 
features in AH patients is the accumulation of intrahepatic monocytes and T cells, we speculate 
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that upregulation of CD38 on monocytes and CD8 T cells could play a role in the infiltration of 
activated circulating monocytes and T cells into the liver. Surprisingly, lower baseline CD38 
expression level on monocytes was the only factor that predicted 3-month and 6-month mortality 
in AH patients (Fig. 2). As stated above, CD38 expressed on monocytes has multiple functions, 
including enhancing adherence to endothelial cells. It is possible that the hyper-adherence of 
activated monocytes to endothelium mediated by overexpression of CD38 impedes instead of 
promotes transmigration of monocytes from blood vessels towards the liver, causing less 
intrahepatic accumulation of macrophages, less liver damage, and lower mortality. 
Alcohol abstinence, the most important aspect for ALD treatment, significantly improves 
the disease outcome and survival, but it does not lead to complete recovery in most ALD 
patients (2). Consistent with this result, clinical scores and liver function in our alcohol abstinent 
AH patients greatly improved, but were still abnormal during the follow-ups (Supporting Table 
1). In addition, some of the upregulated cytokines, including the pro-inflammatory cytokines 
TNF-α and IL-8, were not normalized. The cellular markers appeared to be more responsive to 
alcohol withdraw, as they became similarly expressed between alcohol abstinent AH and HDC. 
Interestingly, monocytes in HDC upregulated CD80 and CD86 expression with alcohol 
abstinence, suggesting a subtle functional impairment of monocytes in the absence of other 
obvious clinical symptoms induced by excessive alcohol consumption.  
At present, there are no effective medical interventions for AH. Beside alcohol cessation, 
corticosteroids are the current pharmacologic options to treat severe AH patients. As 
corticosteroids cause immunosupression, AH patients receiving corticosteroids may be at higher 
risk of infections and have poor treatment outcomes (4, 5). Consistent with the lack of long-term 
clinical benefits of steroid treatment, we did not find additional immunological benefits in alcohol 
abstinent patients at follow-ups. It should be noted that the AH patients treated with steroids had 
more severe diseases than the untreated patients at the study entry.  
In conclusion, we found that HDC showed little evidence of immune activation, whereas 
AH patients had a highly dysregulated expression of multiple immune markers. Abstinence from 
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alcohol consumption greatly but not completely reversed immunological abnormalities, and 
steroid treatments did not appear to have additional long-term immunological benefits. Future 
network analysis of these and other dysregulated immune markers involved in multiple 
pathophysiological aspects of AH should shed light on key immune mediators that are most 
responsive to disease severity/mortality, steroid treatment, and alcohol abstinence (43), and 
provide clues for the development of pharmacological therapies to ameliorate dysregulated 
immune responses in AH patients.  
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 Note: Data are represented as median (interquartile range). HC, healthy controls; AH, patients 
with alcoholic hepatitis; HDC, heavy drinking controls; MELD, end stage liver disease; INR, 
international normalized ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; 
PDN, prednisone; PTX, pentoxifylline. Kruskal-Wallis test with Dunn’s correction for pairwise 
comparisons of continuous variables among HC, AH patients and HDC at enrolment (Day 0). 
Mann Whitney test comparing AH patients versus HDC at Day 180 and Day 360. Chi-square test 
for analysis of categorical variables. *p < 0.05, **p < 0.01, ***p < 0.001 for comparison between 
AH patients and HDC; ǂǂp < 0.01, ǂǂǂp < 0.001 for comparison between AH patients and HC at 
Day 0; §§p < 0.01 for comparison between HDC and HC at Day 0; ns, not significant. 
  
Table 1. Comparison of Characteristics of AH patients and HDC in the TREAT Study Cohort 
Variable 
Day 0 (baseline) Day 180 Day 360 
HC 
(n=20) 
AH 
(n=68) 
HDC 
(n=61) 
p 
AH 
(n=28) 
HDC 
(n=33) 
p 
AH 
(n=18) 
HDC 
(n=26) 
p 
Age at enrollment  
(years) 
38 
(27-53) 
44 
(35-52) 
43 
(36-52) 
ns 
45 
(38-53) 
46 
(37-53) 
ns 
40 
(33-53) 
48 
(39-55) 
ns 
Gender  
(% Male) 
55 61 57 ns 57 59 ns 61 60 ns 
Total drinks in 30 
days 
 
238 
(98-360) 
300 
(198-508) 
** 
0 
(0-8) 
0 
(0-56) 
ns 
0 
(0-2) 
1 
(0-98) 
ns 
Total drinking 
days in 30 days  
 
27 
(17-30) 
27 
(23-30) 
ns 
0 
(0-2) 
0 
(0-16) 
ns 
0 
(0-2) 
1 
(0-23) 
ns 
Complete 
abstinence (%) 
    64 42 ns 72 50 ns 
MELD score  
24 
(19-27) 
6 
(6-7) 
*** 
12 
(8-14) 
7 
(6-8) 
*** 
11 
(8-13) 
7 
(6-8) 
*** 
Creatinine  
(mg/dL) 
0.86 
(0.78-1.02) 
0.75 
(0.58-1.06) 
0.79 
(0.66-0.9) 
ns 
0.78 
(0.6-1) 
0.91 
(0.77-1.07) 
ns 
0.98 
(0.64-1.18) 
0.97 
(0.83-1.10) 
ns 
Total bilirubin 
(mg/dL) 
0.5
ǂǂǂ
 
(0.3-0.6) 
12.9 
(7-19.6) 
0.6 
(0.4-0.7) 
*** 
1.5 
(0.8-3.4) 
0.4 
(0.3-0.5) 
*** 
1.2 
(0.7-1.8) 
0.4 
(0.3-0.7) 
** 
Prothrombin time 
(INR) 
nd 
1.78 
(1.40-2.04) 
0.96 
(0.92-1.01) 
*** 
1.2 
(1.16-1.47) 
1.01 
(0.95-1.04) 
*** 
1.22 
(1.07-1.45) 
0.97 
(0.95-1.06) 
*** 
AST (IU/L) 
17
ǂǂǂ
 
(16-21) 
113 
(88-146) 
24 
(18-29) 
*** 
48 
(32-70) 
20 
(16-23) 
*** 
35 
(28-57) 
21 
(17-26) 
** 
ALT (IU/L) 
13
ǂǂǂ
 
(8-18) 
46 
(30-59) 
22§§ 
(16-28) 
*** 
30 
(20-43) 
15.5 
(11-22) 
*** 
24.5 
(22-34) 
17.5 
(13-27) 
ns 
Treatment with 
PDN and/or PTX 
 58% 0%  60% 0%  56% 0%  
Fasting 30%
ǂǂ
 15% 5%§§ ns 29% 44% ns 11% 35% ns 
Page 21 of 36
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
 Note: Data are represented as median (interquartile range) in pg/ml. HC, healthy controls; AH, 
patients with alcoholic hepatitis; HDC, heavy drinking controls. Kruskal-Wallis test with Dunn’s 
correction for pairwise comparisons among HC, AH patients, and HDC at enrolment (Day 0). 
Mann Whitney test comparing AH patients versus HDC at Day 180 and Day 360. *p < 0.05, **p < 
0.01, ***p < 0.001 for comparison between AH patients and HDC; ǂp < 0.05, ǂǂp < 0.01, ǂǂǂp < 0.001 
for comparison between AH patients and HC at Day 0. 
  
Table 2. Comparison of Plasma Levels of Cytokines/Chemokines in AH patients, HDC, and HC 
Cytokines/chemokines Day 0 Day 180 Day 360 
Types Names 
HC 
n=20 
AH 
n=65 
HDC 
n=61 
AH 
n=28 
HDC 
n=32 
AH 
n=17 
HDC 
n=26 
Pro- 
inflammatory 
IFNα2 
34.5ǂǂ 
(14-55.7) 
74.1 
(51.9-115.6) 
54.9 
(15.3-88.2) 
73.0 
(33.1-92.8) 
80.2 
(38.7-97.4) 
93.4 
(54.9-147.2) 
73.0 
(56.8-92.7) 
TNFα 
6.5ǂǂǂ 
(4.8-10) 
17.9*** 
(12.5-35.8) 
10.2 
(6.8-19.2) 
19.9* 
(10.6-31.1) 
9.8 
(6.6-22.8) 
25.3*** 
(21.8-36.9) 
14.0 
(7.3-20.8) 
IL-6 
1.4ǂǂǂ 
(0.9-3.3) 
13.5*** 
(6.6-36.2) 
2.6 
(0.9-6) 
7.0* 
(3-15.8) 
4.8 
(2.2-7.8) 
7.8** 
(5-14.4) 
2.5 
(0.9-5.1) 
IL-8 
6.9 ǂǂǂ 
(4.9-16.7) 
314.2*** 
(117.9-608.4) 
8.0 
(4.7-15.2) 
52.2*** 
(23.3-102.5) 
8.4 
(5.7-31.6) 
50.9*** 
(25.7-111.4) 
11.0 
(5.3-16.2) 
IP10 
507ǂǂǂ 
(344-610) 
1144*** 
(767-1531) 
629 
(429-847) 
1046** 
(777-1682) 
639 
(409-972) 
1170 
(861-1388) 
790 (570-
1315) 
Anti-
inflammatroy 
IL-4 
4.5 
(4.5-14.7) 
4.5* 
(4.5-17) 
4.5 
(4.5-7.1) 
4.5 
(4.5-18.4) 
4.5 
(4.5-9.8) 
10.3 
(4.5-31.7) 
4.5 
(4.5-9.3) 
IL-9 
1.4 
(1.2-5.7) 
1.4* 
(1.2-5.8) 
1.2 
(0.6-3.6) 
2.3 
(0.6-5.6) 
1.2 
(1.2-3.2) 
4.1* 
(1.2-15.3) 
1.2 
(1.2-2.7) 
IL-10 
2.7ǂǂǂ 
(1.6-5.6) 
14.3*** 
(6.4-35.2) 
5.6 
(1.8-10.3) 
9.9 
(2.8-26.1) 
9.3 
(1.2-12.7) 
17.6* 
(10.9-34.2) 
9.5 
(3.7-15.8) 
MDC 
889 
(768-1091) 
645*** 
(367-1237) 
1167 (795-
1445) 
1409 
(1052-1956) 
1191 
(776-1626) 
2552* 
(1137-2907) 
1296  
(857-1796) 
Growth 
factors 
EGF 
50.9ǂǂ 
(29-102) 
22.8 
(11.6-42.9) 
29.4 
(15.2-50.8) 
33.5 
(13.1-59) 
34.6 
(17.2-71.5) 
42.1 
(28.4-118) 
40.2 
(8.5-83) 
FGF2 
81.6 
(54.1-133.1) 
66.3* 
(49.3-136.7) 
56 
(26.4-95.9) 
89.8 
(41.7-124.6) 
92.8 
(43.1-117) 
155.0** 
(91.9-225.3) 
80.5 
(55-112.1) 
IL-7 
1.4ǂ 
(1.4-3.3) 
8.1* 
(1.4-15.2) 
2.1 
(1.4-9.7) 
7.0 
(1.4-11.2) 
9.0 
(1.4-11.5) 
12.0** 
(7.4-16.1) 
7.0 
(1.4-8.7) 
IL-15 
4.0ǂǂǂ 
(2.1-8.1) 
14.5*** 
(8.5-23.7) 
5.2 
(2-9.3) 
9.2 
(3.6-15.7) 
5.3 
(2.9-14.6) 
8.3 
(3.5-27.6) 
6.7 
(2.8-13.1) 
TGFα 
1.7ǂ 
(1.2-4.6) 
5.8** 
(2.9-12.4) 
2.4 
(1-5.1) 
3.3 
(1.6-7.9) 
3.1 
(0.8-7.9) 
4.0 
(2.4-40.3) 
2.7 
(0.8-5.7) 
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Table 3.  Cross-sectional Analysis of Cell Surface Activation Markers in AH patients and HDC  
Cells 
Surface 
Markers 
Day 0 Day 180 Day 360 
AH 
n=49 
HDC 
n=50 
AH 
n=20 
HDC 
n=22 
AH 
n=16 
HDC 
n=24 
M
o
n
o
c
y
te
s
 
% CD38
+
 
98.8*** 
(97.6-99.5) 
94.6 
(92.8-193.6) 
95.1 
(92.8-97.3) 
93.9 
(90.2-96.6) 
95.4 
(91.9-97.9) 
92.8 
(87.8-96.5) 
% CD69
+
 
64.7** 
(51.1-77.2) 
56.3 
(45.5-124.6) 
67.2 
(53.1-75.1) 
67.5 
(60.8-73.3) 
67.2 
(51.3-74.8) 
69 
(62.9-76.5) 
CD38 MFI 
2928*** 
(2307-3248) 
2094 
(1816-2697) 
1996 
(1627-2570) 
2045 
(1579-2445) 
2168 
(1490-2707) 
1977.5 
(1619-2151) 
CD69 MFI 
431*** 
(378-490) 
376 
(343-818) 
432.5 
(382-517) 
450 
(417-469) 
449 
(373-538) 
460 
(442-495) 
HLA-DR MFI 
2590*** 
(1965-4504) 
5238 
(3289-15094) 
5163 
(2417-5895) 
6157 
(3520-9163) 
6349 
(4570-8263) 
6815 
(5019-7870) 
% CD80
+
 
19.6*** 
(15.6-27.2) 
30.5 
(21.2-80.2) 
32** 
(27.0-43.1) 
49.0 
(39.5-58.8) 
48.8 
(33.7-57.1) 
52.5 
(45.2-62.7) 
CD80 MFI 
503*** 
(455-595) 
625 
(496-1492) 
668* 
(591-816) 
872.5 
(756-1035) 
843 
(666-1035) 
932 
(796-1084) 
CD86 MFI 
442*** 
(377-499) 
541 
(497-1232) 
444*** 
(428-484) 
603 
(523-669) 
588 
(460-660) 
680 
(579-726) 
T
 c
e
lls
 
% CD69
+
 CD4 
1.74*** 
(1.15-2.31) 
1.01 
(0.58-3.12) 
0.99 
(0.77-1.29) 
1.04 
(0.73-1.32) 
0.47 
(0.41-0.560) 
0.52 
(0.38-0.66) 
% CD38
+
 CD8 
60.9*** 
(44.2-73.8) 
43.2 
(38.3-110.8) 
52.4 
(39.6-60.3) 
42.65 
(31.3-53.0) 
49.6 
(34.9-61.7) 
43.3 
(37.2-51.6) 
% CD69
+
 CD8 
11.4** 
(5.1-20.7) 
6.7 
(3.8-19.7 
7.8 
(4.4-17.3) 
9.3 
(6.7-13.2) 
3.6* 
(2.7-7.3) 
7.6 
(4.9-12.7) 
% CD8 
13.2*** 
(9.9-17.4) 
17.9 
(14.9-42) 
15.6 
(12.6-18.9) 
16.7 
(13.3-19.1) 
15.9 
(9.3-21.8) 
17.2 
(14.3-19.6) 
% IFN-γ
+
 CD4 
3.51* 
(1.43-5.29) 
5.4 
(3.16-17.02) 
1.32 
(0.28-2.40) 
2.39 
(1.19-3.91) 
1.83 
(0.97-4.50) 
3.84 
(2.37-5.90) 
B
 c
e
lls
 
% CD80
+
 
14.1** 
(8.2-22.2) 
20.8 
(12.9-55.2) 
27.5 
(16.0-32.6) 
22.6 
(15.0-32.1) 
26.2 
(17.4-38.4) 
28.1 
(21.8-30.1) 
CD80 MFI 
449** 
(371-546) 
537 
(456-599) 
609 
(499-663) 
554 
(475-658) 
589 
(516-739) 
634 
(570-665) 
 
Note: Data are represented as median (interquartile range). AH, patients with alcoholic 
hepatitis; HDC, heavy drinking controls; MFI: mean fluorescent intensity. Mann Whitney test 
comparing AH patients versus HDC at enrolment (Day 0), day 180 and day 360, *p < 0.05, **p < 
0.01, ***p < 0.001. 
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Fig. 1. Plasma levels of proinflammatory and anti-inflammatory cytokines/chemokines in AH and HDC. 
Scatter plots demonstrating the plasma levels of IL-6, IL-8, and MDC in AH patients and HDC as determined 
by either multiplex assays (A) or ELISA (B). Mann Whitney test was used to compare the levels of these 
cytokines/chemokines in AH versus HDC at day 0, day 180, and day 360. (C) Spearman correlation analysis 
between plasma cytokine levels in all samples quantified by both multiplex assays and ELISA (n=210). r, 
Spearman correlation coefficient. AH, patients with alcoholic hepatitis; HDC, heavy drinking controls; *p < 
0.05; **p < 0.01; ***p < 0.001; ns, not significant; D0, day 0; D180, day 180; and D360, day 360. 
Horizontal lines represent the median.  
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Fig. 2. Kaplan-Meier survival curves and comparison of immune markers in steroid-treated and untreated AH 
patients. (A) Kaplan-Meier curves showing 3- and 6-month survival according to baseline CD38 expression 
levels on monocytes. The mean fluorescent intensity (MFI) of 2,999 was used as the cut-off to define 
patients with low (n=17) or high (n=18) CD38 expression. (B) Scatter plots of plasma IL-6, IFNα-2, IL-8, 
MDC levels, CD38-expressing monocytes, and IFN-γ-expressing CD4 T cells in steroid ± pentoxifylline-
treated (Treated) and non-treated (NT) patients. Mann Whitney test for comparisons at days 0 (D0), 180 
(D180), and 360 (D360). Horizontal lines represent the median; *p < 0.05; **p < 0.01; and ns, not 
significant.  
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Fig. 3. Longitudinal analysis of plasma levels of IL-8 and MDC in AH patients and HDC who were abstinent 
from alcohol. Friedman rank sum test with Dunn’s corrections for comparing cytokine/chemokine 
concentrations at day 0 with day 180 or day 360 (n=10 for both AH and HDC). *p < 0.05, **p < 0.01, **p 
< 0.001. ns, not significant; D0, day 0; D180, day 180; and D360, day 360.  
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Fig. 4. Longitudinal analysis of the effects of alcohol abstinence on expression levels of cell surface markers 
in AH patients and HDC. Friedman rank sum test with Dunn’s corrections for comparing surface marker 
expression at day 0 with day 180 or day 360 (n=7 for AH and n=9 for HDC). *p < 0.05, **p < 0.01. ns, not 
significant; D0, day 0; D180, day 180; D360, day 360; and MFI, mean fluorescent intensity.  
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Note: Data are shown as median (interquartile range). AH, patients with alcoholic hepatitis; 
HDC, heavy drinking controls; MELD, end stage liver disease; INR, international normalized 
ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase. Mann Whitney test and 
Chi-square test comparing AH patients versus HDC for continuous and categorical variables, 
respectively. *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant. 
   
Supporting Table 1. Comparison of Characteristics of Abstinent AH and HDC subjects 
at days 180 and 360 
Variable 
Day 180 Day 360 
AH 
(n=17) 
HDC 
(n=17) p 
AH 
(n=13) 
HDC 
(n=13) p 
Age at enrollment  
(years) 
46 
(40-53) 
42 
(32-47) ns 
45 
(34-53) 
44 
(37-50) ns 
Gender (% Male) 53 76 ns 62 62 ns 
MELD score 13 (9-14) 
7 
(6-8) *** 
10 
(8-13) 
7 
(6-8) ** 
Creatinine  (mg/dL) 0.78 (0.68-1.02) 
0.91 
(0.86-1.04) ns 
1.01 
(0.96-1.27) 
0.95 
(0.87-1.06) ns 
Total bilirubin (mg/dL) 1.6 (0.8-3) 
0.4 
(0.3-0.4) *** 
0.8 
(0.6-1.3) 
0.4 
(0.3-0.5) ** 
Prothrombin time (INR) 1.24 (1.17-1.53) 
1.0 
(0.96-1.05) *** 
1.2 
(1.06-1.3) 
1.02 
(0.96-1.1) * 
AST (IU/L) 38 (31-61) 
17 
(16-22) *** 
31 
(26-35) 
20 
(16-24) *** 
ALT (IU/L) 26 (19-40) 
13 
(11-23) ** 
24 
(21-32) 
17 
(13-25) ns 
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Note: AH, patients with alcoholic hepatitis; HDC, heavy drinking controls; HC, healthy controls. 
Kruskal-Wallis test with Donn’s correction for pairwise comparison among AH patients, HDC, 
and HC at baseline (Day 0). Mann Whitney test comparing AH patients versus HDC at day 180 
and day 360. D0: AH patients n=65, HDC n=61; D180: AH patients n=28, HDC n=32; D360: AH 
patients n=17, HDC n=26; HC n=20. *p < 0.05, **p < 0.01, ***p < 0.001. 
Supporting Table 2. Fold Changes in Median Levels of Plasma 
Cytokine/chemokine among AH, HDC, and HC Subjects 
Cytokines/ 
Chemokines 
Day 0 Day 180 Day 360 
 AH vs HDC  AH vs HC  HDC vs HC AH vs HDC AH vs HDC 
IL-8 39.2*** 45.6*** 1.2 6.2*** 4.6*** 
IL-6 5.1*** 9.8*** 1.9 1.5* 3.1** 
IL-7 3.8* 5.8* 1.5 0.8 1.7** 
IL-15 2.8*** 3.7*** 1.3 1.7 1.2 
IL-10 2.5*** 5.2*** 2.0 1.1 1.9* 
TGF-a 2.4** 3.3* 1.4 1.1 1.5 
IL-1B 2.4 1.9 0.8 1.4 9.0* 
IP-10 1.8*** 2.3*** 1.2 1.6** 1.5 
GM-CSF 1.8 2.4 1.4 1.4 1.4* 
TNFa 1.8*** 2.8*** 1.6 2.0* 1.8*** 
IL-2 1.7 1.2 0.7 0.7 2.0* 
IL-12P40 1.6 1.3 0.8 1.2 4.5 
IL-1RA 1.6 2.3 1.5 1.3 2.4 
IL-1a 1.5 3.0 2.0 0.7 1.6 
VEGF 1.4 1.1 0.7 0.9 1.3* 
IL-17A 1.4 2.1 1.5 1.3 1.7** 
IFNa-2 1.4 2.1** 1.6 0.9 1.3 
IL12P70 1.3 3.8 2.8 1.0 2.1 
Fractalkine 1.3 1.6 1.2 1.2 2.1* 
G-CSF 1.3 2.4 1.9 0.6 1.4 
MIP-1B 1.2 1.4 1.1 1.0 1.4 
MIP-1a 1.2 0.9 0.7 1.2 1.4 
FGF-2 1.2* 0.8 0.7 1.0 1.9** 
IFNy 1.2 1.9 1.6 1.0 1.5 
IL-9 1.1* 1.0 0.8 1.9 3.4* 
MCP-1 1.1 1.2 1.1 1.1 0.9 
GRO 1.1 1.3 1.1 0.6 0.8 
MCP-3 1.0 0.2 0.2 5.2 7.3 
IL-13 1.0 0.4 0.4 1.5 12.8 
IL-3 1.0 1.0 1.0 1.0 1.4 
IL-4 1.0* 1.0 1.0 1.0 2.3 
IL-5 1.0 2.0 2.0 1.1 1.6 
TNFB 1.0 0.6 0.6 2.1 17.8 
Flt-3L 1.0 0.5 0.5 2.5 3.3 
Eotaxin 0.9 1.1 1.2 0.9 0.8 
sCD40L 0.8 0.9 1.2 1.1 0.9 
EGF 0.8 0.4** 0.6 1.0 1.0 
MDC 0.6*** 0.7 1.3 1.2 2.0* 
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Supporting Table 3.  Fold Changes in Expression Levels of Cell 
Activation Markers between AH and HDC Subjects 
Cells Surface Marker Day 0 Day 180 Day 360 
Mo
no
cyt
es
 
% CD38+ 1.04*** 1.01 1.03 
% CD69+ 1.15** 1.00 0.97 
CD38 MFI 1.4*** 0.98 1.10 
CD69 MFI 1.15*** 0.96 0.98 
HLA-DR MFI 0.49*** 0.84 0.93 
% CD80+ 0.64*** 0.65** 0.93 
CD80 MFI 0.81*** 0.77* 0.90 
CD86 MFI 0.82*** 0.74*** 0.86 
T c
ells
 
% CD69+ CD4 1.73*** 0.96 0.90 
% CD38+ CD8 1.41*** 1.23 1.15 
% CD69+ CD8 1.70** 0.84 0.48* 
% CD4 1.03 1.20 1.05 
% CD8 0.77*** 0.89 0.72 
% IFN-+ CD4 0.65* 0.55 0.48 
% IFN-+ CD8 0.77 0.89 0.72 
B c
ells
 % CD80+ 0.68** 1.21 0.93 
CD80 MFI 0.84** 1.10 0.93 
HLA-DR MFI 0.80 1.21 0.97 
 
Note: AH, alcoholic hepatitis; HDC, heavy drinking controls. Mann Whitney test comparing AH 
patients versus HDC at baseline (Day 0), day 180 and day 360. Day 0: AH patients n=49, HDC 
n=50; Day 180: AH patients n=20, HDC n=22; Day 360: AH patients n=16, HDC n=24. *p < 
0.05, **p < 0.01, ***p < 0.001. 
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Supporting Table 4. Correlation Coefficients and Statistical Significance between 
Immune Parameters and Clinical and Biochemical Data in AH Patients 
 Immune markers 
MELD 
score Creatinine  
Total 
bilirubin INR ALT AST 
# of drinks 
in the 
prior 30 
days 
Neutro
phils Count 0.46*** ns 0.45*** 0.3* ns 0.26* ns 
Cy
tok
ine
s/c
he
mo
kin
es
 IL-6 0.42***  ns 0.43***  0.31** ns 0.39*** ns 
IL-8 0.65*** 0.32* 0.74***  0.45*** 0.21* 0.58*** 0.52*** 
IL-15 0.24* ns 0.29** 0.23* ns 0.24** ns 
MDC -0.46*** ns -0.57*** -0.38*** -0.28** -0.44*** -0.43*** 
TGF-  0.24* ns 0.29* 0.27** ns ns ns 
TNF ns 0.29** ns ns ns ns ns 
Mo
no
cyt
es
 
% CD38 0.54*** ns 0.58*** 0.53*** ns 0.26* 0.36*** 
CD38 MFI 0.38*** ns 0.43*** 0.36*** ns 0.32** 0.29** 
% CD80+ -0.35** ns -0.44*** ns -0.31** -0.49*** -0.33** 
CD80 MFI -0.35** ns -0.44*** ns -0.3** -0.48*** -0.33** 
CD86 MFI ns ns ns ns -0.25* -0.32** ns 
HLA-DR 
MFI -0.36*** ns -0.42*** -0.27* ns -0.35*** ns 
B c
ells
 % CD80 -0.26* ns -0.3** ns ns -0.33** -0.22* 
CD80 MFI -0.30** ns -0.33** ns ns -0.35*** -0.24* 
T c
ells
 
CD69+ 
CD4 0.40*** ns 0.50*** 0.30** 0.28** 0.45*** 0.38*** 
% CD8 -0.28* ns -0.27* -0.26* ns ns ns 
% CD38+ 
CD8 0.30** ns 0.34** ns ns ns ns 
% CD69+ 
CD8 ns ns 0.24* ns ns 0.36*** ns 
 
Note: AH, alcoholic hepatitis; MELD, end stage liver disease; INR, international relative ratio for 
prothrombin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase. The 
numbers represent Spearman’s coefficients, *p < 0.05, **p < 0.01, ***p < 0.001, ns: non-
significant. Negative numbers represent negative correlations. N=63 for neutrophil counts, 
n=108 for cytokines/chemokines, n=82 for cellular markers. 
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Note: AH, alcoholic hepatitis; Treated, patients treated with corticosteroids alone or with both 
corticosteroids and pentoxifylline at study entry; NT, AH patients not treated with the drugs. Day 
180 and Day 360 samples were from AH patients who were abstinent at follow up. Mann 
Whitney test comparing treated versus untreated AH patients at baseline (Day 0), day 180 and 
day 360. Day 0: Treated n=25-34, NT n=22-28; Day 180: Treated n=4-9, NT n=7-8; Day 360: 
Treated n=5-7, NT n=6-7. *p < 0.05, **p < 0.01, ***p < 0.001. 
 
   
Supporting Table 5. Fold Changes in Median Levels of Immune Markers between 
Corticosteroids ± pentoxifylline-treated and -untreated AH Patients  
Immune markers Day 0 Day 180 Day 360 
Types Names Treated vs. NT p 
Treated 
vs. NT p 
Treated 
vs. NT p 
Markers Lower 
in treated AH 
patients 
G‐CSF  0.4 *** 0.9 ns 1.2 ns 
IL‐6  0.5 * 0.8 ns 0.9 ns 
IL‐7  0.5 0.07 0.9 ns 1.3 ns 
MDC  0.5 ** 1.8 ns 1.3 ns 
IL‐9  0.7 0.06 1.1 ns 0.4 ns 
TNFa  0.7 0.08 1.0 ns 0.8 ns 
IFNa2  0.8 * 1.1 ns 1.5 ns 
Fractalkine  0.8 * 0.9 ns 0.6 ns 
Markers Higher 
in treated AH 
patients 
IL‐8  2.1 * 2.3 ns 1.2 ns 
Eotaxin  1.8 * 1.9 ns 1.4 ns 
% IFN-+ 
CD4 T cells 2.7 * 0.5 ns 0.6 ns 
% IFN-+ 
CD8 T cells 3.2 ** 1.9 ns 1.7 ns 
% CD38+ 
mononcytes 1.0 *** 1.1 * 1.1 ** 
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Supporting Table 6. Comparison of Plasma Cytokine/chemokine Levels in 
Abstinent Subjects at Days 180 and 360 
Cytokines/chemokines Day 180 Day 360 
Types Names AH  (n=17) 
HDC 
(n=17) p 
AH  
(n=13) 
HDC 
(n=13) p 
Pro-inflammatory 
IFN 77.5 (72.0-96.2) 
77.5 
(46.8-97.4) ns 
82.9 
(51.9-147.2) 
72 
(60.7-93.4) ns 
TNF 27.7 (15.5-32.0) 
8.3 
(5.6-13.4) ** 
27.3 
(21.8-45.0) 
11.9 
(5.1-17.9) ** 
IL-6 7.3 (4.9-19.3) 
4.2 
(0.9-7.8) * 
6.2 
(4.0-8.5) 
2.4 
(1.4-5.7) * 
IL-8 40.4 (23.5-65.2) 
8.3 
(5.8-47.6) * 
44.2 
(25.7-111.4) 
9.4 
(5.4-22.8) ** 
IP10 1317 (882-1764) 
648 
(324-1041) ** 
1169 
(861-1274) 
689 
(472-1214) ns 
Anti-inflammatory 
 
IL-4 8.5 (4.5-18.4) 
4.5 
(4.5-8.1) ns 
8.7 
(4.5-31.7) 
4.5 
(4.5-8.7) ns 
IL-9 2.8 (1.2-5.6) 
1.9 
(1.2-4.0) ns 
4.1 
(1.2-15.3) 
1.2 
(0.9-1.9) ns 
IL-10 10.9 (2.8-27.4) 
8.3 
(1.1-11.4) ns 
17.5 
(7.6-34.2) 
9.3 
(7.6-11.7) ns 
MDC 1442 (1056-2492) 
1201 
(718-1575) ns 
2552 
(1137-2845) 
1297 
(1099-1509) ns 
Growth factors 
EGF 33.9 (13.1-52.8) 
35.8 
(18.1-77.6) ns 
42.1 
(28.4-118) 
64.6 
(41.6-108.1) ns 
FGF2 102.8 (66.3-122) 
91.9 
(62.4-104.3) ns 
109.1 
(83.6-225.3) 
83.6 
(58.2-91.9) * 
IL-7 7.2 (4.7-10.9) 
5.5 
(1.4-10.1) ns 
12 
(8.4-18.9) 
7.4 
(1.4-8.7) * 
IL-15 10.7 (5.3-23.1) 
6.4 
(1.3-17.9) ns 
6.5 
(3.5-27.6) 
4.5 
(2.4-13.3) ns 
TGF 4.7 (2.7-13) 
2.5 
(0.8-16.1) ns 
4.0 
(2-40.3) 
5.1 
(2.2-13.6) ns 
 
Note: Data are represented as median (interquartile range) in pg/ml. AH, patients with alcoholic 
hepatitis; HDC, heavy drinking controls. Mann Whitney test comparing AH patients vs HDC at 
day 180 and day 360. *p < 0.05, **p < 0.01, ns: not significant. 
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Supporting Fig. S1. CD38 expression levels on monocytes predicted AH mortality. Scatter 
plot of baseline CD38 expression levels on monocytes in AH patients who died within 6 months 
after recruitment (non-survivors) and those survived (survivors). Horizontal lines represent the 
median. Mann Whitney test was used for the statistical analysis. *p < 0.05. 
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 Supporting Fig. S2. Differences in clinical characteristics between AH patients treated 
with prednisone ± pentoxifylline and untreated AH patients at enrolment. Mann Whitney 
test was used to compare MELD score, total bilirulin, international normalized ratio for 
prothrombin time (INR), creatinine, alanine aminotransferase (ALT), and aspartate 
aminotransferase ( AST) (n=36, for treated  and n=28-29 for untreated). Horizontal line 
represent the median. Mann Whitney test was used for the statistical analysis. *p < 0.05, **p < 
0.01; ***p < 0.001.  
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Supporting Fig. S3. Recovery of CD80 expression on B cells in AH patients after alcohol 
cessation. Longitudinal analysis of CD80 expression levels on B cells in AH patients and HDC 
controls. Friedman rank sum test comparing surface marker expression at day 0 with day 180 
and 360 (Dunn’s corrections for multiple testing of data, n=7 for AH patients and n=9 for HDC). 
*p < 0.05. ns, not significant. MFI, mean fluorescent intensity. 
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